首页 > 最新文献

AIDS Research and Therapy最新文献

英文 中文
Barriers to viral load suppression among adolescents living with HIV on anti-retroviral therapy: a retrospective study in Tanga, Tanzania. 接受抗逆转录病毒疗法的青少年艾滋病毒感染者抑制病毒载量的障碍:在坦桑尼亚坦噶进行的一项回顾性研究。
IF 2.1 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2024-05-22 DOI: 10.1186/s12981-024-00622-7
Stella Emmanuel Mushy, Expeditho Mtisi, Simon Mkawe, Eric Mboggo, John Ndega, Khadija I Yahya-Malima, Denice Kamugunya, Edwin Samuel Kilimba, Boniface S Mlay, Aisa Muya, Frida Ngalesoni

Background: Despite the decreased incidence of the human immunodeficiency virus (HIV) in Tanzania, the number of adolescents living with HIV is increasing. This study aimed to describe factors independently associated with viral load non-suppression among adolescents living with HIV (ALHIV) on ART in the Tanga region.

Methods: We conducted a retrospective study of routinely collected data from ALHIV on ART from October 2018 to April 2022. We extracted data from the Care and Treatment Clinics form number 2 (CTC2) database that included age, sex, BMI, World Health Organization HIV clinical disease stage, marital status, ART duration, viral load suppression, facility level, and Dolutegravir (DTG)-based regimen. We did descriptive analysis using frequencies to describe the study participants' socio-demographic and clinical characteristics. The Cox proportional hazard regression model was used to identify factors associated with viral load non-suppression (VLS). Viral load non-suppression was defined as viral load ≥ 1000 copies/ml. A total of 4735 ALHIV on ART were extracted from CTC2, then 2485 were excluded (2186 missed viral load results, 246 were lost to follow-up, and 53 deaths).

Results: 2250 ALHIV on ART were tested for viral load, of whom 2216 (98.62%) adolescents were on first-line ART, and 2024 (89.96%) participants were virally suppressed, while 226 (10.04%) were virally non-suppressed. In addition, 2131 (94.71%) of participants were using a DTG-based regimen; of them, 1969 (92.40%) were virally suppressed. Not using a DTG-based regimen (HR: 9.36, 95% CI 3.41-15.31) and dispensary facility level (HR: 3.61, 95% CI 1.44-7.03) were independently associated with increased hazard for viral load non-suppression. In addition, adolescents aged between 15 and 19 years are less likely to be virally suppressed (HR: 0.55, 95% CI 0.30-0.99).

Conclusions: The dispensary facility level and not using a DTG-based regimen were significantly associated with viral load non-suppression. HIV intervention strategies should ensure a DTG-based regimen utilization in all adolescents living with HIV, and techniques used by higher-level health facilities should be disseminated to lower-level facilities.

背景:尽管坦桑尼亚的人类免疫缺陷病毒(HIV)发病率有所下降,但感染 HIV 的青少年人数却在不断增加。本研究旨在描述坦噶地区接受抗逆转录病毒疗法的艾滋病病毒感染青少年(ALHIV)中与病毒载量不抑制独立相关的因素:我们对 2018 年 10 月至 2022 年 4 月期间常规收集的接受抗逆转录病毒疗法的 ALHIV 数据进行了回顾性研究。我们从护理和治疗诊所第 2 号表格(CTC2)数据库中提取了数据,其中包括年龄、性别、体重指数、世界卫生组织艾滋病临床疾病分期、婚姻状况、抗逆转录病毒疗法持续时间、病毒载量抑制率、设施级别和基于多鲁替拉韦(DTG)的治疗方案。我们使用频率进行描述性分析,以描述研究参与者的社会人口学和临床特征。我们使用 Cox 比例危险回归模型来确定与病毒载量未抑制(VLS)相关的因素。病毒载量不抑制定义为病毒载量≥1000拷贝/毫升。结果:2250 名接受抗逆转录病毒疗法的 ALHIV 接受了病毒载量检测,其中 2216 名(98.62%)青少年接受了一线抗逆转录病毒疗法,2024 名(89.96%)参与者的病毒载量得到抑制,226 名(10.04%)参与者的病毒载量未得到抑制。此外,2131 人(94.71%)正在使用以 DTG 为基础的治疗方案,其中 1969 人(92.40%)的病毒已被抑制。未使用基于 DTG 的治疗方案(HR:9.36,95% CI 3.41-15.31)和药房设施水平(HR:3.61,95% CI 1.44-7.03)与病毒载量未被抑制的风险增加独立相关。此外,15 至 19 岁的青少年病毒载量抑制的可能性较低(HR:0.55,95% CI 0.30-0.99):结论:药房设施水平和未使用基于 DTG 的治疗方案与病毒载量未得到抑制有很大关系。艾滋病干预策略应确保所有感染艾滋病病毒的青少年都使用以DTG为基础的治疗方案,并应将较高级医疗机构使用的技术推广到较低级医疗机构。
{"title":"Barriers to viral load suppression among adolescents living with HIV on anti-retroviral therapy: a retrospective study in Tanga, Tanzania.","authors":"Stella Emmanuel Mushy, Expeditho Mtisi, Simon Mkawe, Eric Mboggo, John Ndega, Khadija I Yahya-Malima, Denice Kamugunya, Edwin Samuel Kilimba, Boniface S Mlay, Aisa Muya, Frida Ngalesoni","doi":"10.1186/s12981-024-00622-7","DOIUrl":"10.1186/s12981-024-00622-7","url":null,"abstract":"<p><strong>Background: </strong>Despite the decreased incidence of the human immunodeficiency virus (HIV) in Tanzania, the number of adolescents living with HIV is increasing. This study aimed to describe factors independently associated with viral load non-suppression among adolescents living with HIV (ALHIV) on ART in the Tanga region.</p><p><strong>Methods: </strong>We conducted a retrospective study of routinely collected data from ALHIV on ART from October 2018 to April 2022. We extracted data from the Care and Treatment Clinics form number 2 (CTC2) database that included age, sex, BMI, World Health Organization HIV clinical disease stage, marital status, ART duration, viral load suppression, facility level, and Dolutegravir (DTG)-based regimen. We did descriptive analysis using frequencies to describe the study participants' socio-demographic and clinical characteristics. The Cox proportional hazard regression model was used to identify factors associated with viral load non-suppression (VLS). Viral load non-suppression was defined as viral load ≥ 1000 copies/ml. A total of 4735 ALHIV on ART were extracted from CTC2, then 2485 were excluded (2186 missed viral load results, 246 were lost to follow-up, and 53 deaths).</p><p><strong>Results: </strong>2250 ALHIV on ART were tested for viral load, of whom 2216 (98.62%) adolescents were on first-line ART, and 2024 (89.96%) participants were virally suppressed, while 226 (10.04%) were virally non-suppressed. In addition, 2131 (94.71%) of participants were using a DTG-based regimen; of them, 1969 (92.40%) were virally suppressed. Not using a DTG-based regimen (HR: 9.36, 95% CI 3.41-15.31) and dispensary facility level (HR: 3.61, 95% CI 1.44-7.03) were independently associated with increased hazard for viral load non-suppression. In addition, adolescents aged between 15 and 19 years are less likely to be virally suppressed (HR: 0.55, 95% CI 0.30-0.99).</p><p><strong>Conclusions: </strong>The dispensary facility level and not using a DTG-based regimen were significantly associated with viral load non-suppression. HIV intervention strategies should ensure a DTG-based regimen utilization in all adolescents living with HIV, and techniques used by higher-level health facilities should be disseminated to lower-level facilities.</p>","PeriodicalId":7503,"journal":{"name":"AIDS Research and Therapy","volume":"21 1","pages":"35"},"PeriodicalIF":2.1,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11112887/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141080436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacokinetics of tenofovir alafenamide, emtricitabine, and dolutegravir in a patient on peritoneal dialysis. 一名腹膜透析患者体内替诺福韦-阿拉非那胺、恩曲他滨和多罗特拉韦的药代动力学。
IF 2.1 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2024-05-21 DOI: 10.1186/s12981-024-00616-5
Sandra Abdul Massih, Mohamed G Atta, Chloe L Thio, Jeffrey A Tornheim, Edward J Fuchs, Rahul P Bakshi, Mark A Marzinke, Craig W Hendrix, Ethel D Weld

Introduction: Peritoneal dialysis (PD) is an effective renal replacement modality in people with HIV (PWH) with end-stage kidney disease (ESKD), particularly those with residual kidney function. Data on pharmacokinetics (PK) of antiretrovirals in patients on peritoneal dialysis are limited.

Methods: A single-participant study was performed on a 49-year-old gentleman with ESKD on PD and controlled HIV on once daily dolutegravir (DTG) 50 mg + tenofovir alafenamide (TAF) 25 mg / emtricitabine (FTC) 200 mg. He underwent serial blood plasma, peripheral blood mononuclear cell, and urine PK measurements over 24 h after an observed DTG + FTC/TAF dose.

Results: Plasma trough (Cmin) concentrations of TAF, tenofovir (TFV), FTC, and DTG were 0.05, 164, 1,006, and 718 ng/mL, respectively. Intracellular trough concentrations of TFV-DP and FTC-TP were 1142 and 11,201 fmol/million cells, respectively. Compared to published mean trough concentrations in PWH with normal kidney function, observed TFV and FTC trough concentrations were 15.5- and 20-fold higher, while intracellular trough concentrations of TFV-DP and FTC-TP were 2.2-fold and 5.4-fold higher, respectively. TFV and FTC urine levels were 20 times lower than in people with normal GFR.

Conclusions: In a single ESKD PWH on PD, daily TAF was associated with plasma TFV and intracellular TFV-DP trough concentrations 15-fold and 2-fold higher than those of people with uncompromised kidney function, potentially contributing to nephrotoxicity. This suggests that TFV accumulates on PD; thus, daily TAF in PD patients may require dose adjustment or regimen change to optimize treatment, minimize toxicity, and preserve residual kidney function.

简介:腹膜透析(PD)是终末期肾病(ESKD)艾滋病病毒感染者(PWH),尤其是残余肾功能者的一种有效的肾脏替代方式。腹膜透析患者体内抗逆转录病毒药物的药代动力学(PK)数据十分有限:我们对一名 49 岁的腹膜透析 ESKD 患者进行了单人研究,该患者每天服用一次多托曲韦 (DTG) 50 毫克 + 替诺福韦-阿拉非那胺 (TAF) 25 毫克/恩曲他滨 (FTC) 200 毫克,控制了艾滋病病毒感染。在观察DTG + FTC/TAF剂量后的24小时内,他接受了连续的血浆、外周血单核细胞和尿液PK测定:结果:TAF、替诺福韦(TFV)、FTC和DTG的血浆谷浓度(Cmin)分别为0.05、164、1,006和718纳克/毫升。TFV-DP和FTC-TP的细胞内谷浓度分别为1142和11201 fmol/百万细胞。与已公布的肾功能正常的 PWH 平均谷浓度相比,观察到的 TFV 和 FTC 谷浓度分别高出 15.5 倍和 20 倍,而 TFV-DP 和 FTC-TP 的细胞内谷浓度分别高出 2.2 倍和 5.4 倍。TFV和FTC尿液水平比GFR正常者低20倍:结论:在一名服用 PD 的 ESKD PWH 中,每日 TAF 与血浆 TFV 和细胞内 TFV-DP 谷浓度相关,分别是肾功能未受损人群的 15 倍和 2 倍,这可能会导致肾毒性。这表明,TFV会在PD上蓄积;因此,PD患者每日服用TAF可能需要调整剂量或改变治疗方案,以优化治疗、减少毒性并保护残余肾功能。
{"title":"Pharmacokinetics of tenofovir alafenamide, emtricitabine, and dolutegravir in a patient on peritoneal dialysis.","authors":"Sandra Abdul Massih, Mohamed G Atta, Chloe L Thio, Jeffrey A Tornheim, Edward J Fuchs, Rahul P Bakshi, Mark A Marzinke, Craig W Hendrix, Ethel D Weld","doi":"10.1186/s12981-024-00616-5","DOIUrl":"10.1186/s12981-024-00616-5","url":null,"abstract":"<p><strong>Introduction: </strong>Peritoneal dialysis (PD) is an effective renal replacement modality in people with HIV (PWH) with end-stage kidney disease (ESKD), particularly those with residual kidney function. Data on pharmacokinetics (PK) of antiretrovirals in patients on peritoneal dialysis are limited.</p><p><strong>Methods: </strong>A single-participant study was performed on a 49-year-old gentleman with ESKD on PD and controlled HIV on once daily dolutegravir (DTG) 50 mg + tenofovir alafenamide (TAF) 25 mg / emtricitabine (FTC) 200 mg. He underwent serial blood plasma, peripheral blood mononuclear cell, and urine PK measurements over 24 h after an observed DTG + FTC/TAF dose.</p><p><strong>Results: </strong>Plasma trough (Cmin) concentrations of TAF, tenofovir (TFV), FTC, and DTG were 0.05, 164, 1,006, and 718 ng/mL, respectively. Intracellular trough concentrations of TFV-DP and FTC-TP were 1142 and 11,201 fmol/million cells, respectively. Compared to published mean trough concentrations in PWH with normal kidney function, observed TFV and FTC trough concentrations were 15.5- and 20-fold higher, while intracellular trough concentrations of TFV-DP and FTC-TP were 2.2-fold and 5.4-fold higher, respectively. TFV and FTC urine levels were 20 times lower than in people with normal GFR.</p><p><strong>Conclusions: </strong>In a single ESKD PWH on PD, daily TAF was associated with plasma TFV and intracellular TFV-DP trough concentrations 15-fold and 2-fold higher than those of people with uncompromised kidney function, potentially contributing to nephrotoxicity. This suggests that TFV accumulates on PD; thus, daily TAF in PD patients may require dose adjustment or regimen change to optimize treatment, minimize toxicity, and preserve residual kidney function.</p>","PeriodicalId":7503,"journal":{"name":"AIDS Research and Therapy","volume":"21 1","pages":"34"},"PeriodicalIF":2.1,"publicationDate":"2024-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11110198/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141075160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Magnitude of intestinal parasitic infections and its determinants among HIV/AIDS patients attending at antiretroviral treatment centers in East and West Gojam Zones, Northwest, Ethiopia: institution based cross-sectional study. 在埃塞俄比亚西北部东戈贾姆区和西戈贾姆区抗逆转录病毒治疗中心就诊的艾滋病毒/艾滋病患者肠道寄生虫感染的严重程度及其决定因素:基于机构的横断面研究。
IF 2.1 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2024-05-16 DOI: 10.1186/s12981-024-00618-3
Mengistu Endalamaw, Abel Alemneh, Gashaw Azanaw Amare, Abebe Fenta, Habtamu Belew

Background: Intestinal parasitic infections (IP) are a major source of morbidity in people living with Human immunodeficiency virus (HIV), particularly in resource-limited settings, mostly as a result of high viral load. Hence, this study aimed to investigate the magnitude of intestinal parasitic infections and its determinants among patients with HIV/AIDS attending public health facilities in East and West Gojam Zones in Ethiopia.

Methods: Institution-based cross-sectional study was conducted on 327 people living with HIV visiting public health facilities from December 2022 to May 2023. A simple random sampling technique was used to recruit participants. Face-to-face interviews were used to collect socio-demographics and determinants. The fresh stool was collected from each patient, transported, and tested in accordance with laboratory standard operating procedures of wet mount, formol-ether concentration technique, and modified acid-fast staining. Data were entered and analyzed in the statistical package for Social Science (SPSS) version 20. A 95% CI with p-value < 0.05 was considered statistically significant.

Results: The overall prevalence of IP in patients with HIV/AIDS was 19.3% (63/327). Hookworm was the most identified parasite 33.3% (21/63) followed by E.histolytica 17% (11/63) and G.lamblia 14.3% (9/63). Parasitic infections were significantly higher among viral load > 1000cps/ml (p = 0.035), WHO stage 4 (p = 0.002), CD4 < 200 cell/mm3 (p = 0.001), and bare foot walking (p = 0.001).

Conclusion: IP infections are moderately high among patients with HIV/AIDS in the study area. The proportion of parasites was greatly affected by high viral load, WHO stage 4, CD4 < 200 cell/mm3, and being barefoot; this gives valuable insight to health professionals, health planners and community health workers. As a result, viral load monitoring, and WHO stage controlling were periodically assessed in patients with HIV/AIDS. Health education, awareness creation, routine stool examination, and environmental hygiene were regularly advocated to increase the life of patients with HIV/AIDS.

背景:肠道寄生虫感染(IP)是人类免疫缺陷病毒(HIV)感染者发病的一个主要原因,尤其是在资源有限的环境中,这主要是高病毒载量造成的。因此,本研究旨在调查在埃塞俄比亚东戈贾姆区和西戈贾姆区公共卫生机构就诊的艾滋病毒/艾滋病患者中肠道寄生虫感染的严重程度及其决定因素:在2022年12月至2023年5月期间,对前往公共卫生机构就诊的327名艾滋病毒感染者进行了基于机构的横断面研究。采用简单随机抽样技术招募参与者。通过面对面访谈收集社会人口统计数据和决定因素。每位患者的新鲜粪便均被收集、运送,并按照湿装载、甲醇-乙醚浓缩技术和改良酸-ast 染色的实验室标准操作程序进行检测。数据用社会科学统计软件包(SPSS)第 20 版进行输入和分析。95% CI 及 p 值 结果:艾滋病毒/艾滋病患者中 IP 的总发病率为 19.3%(63/327)。钩虫是最常见的寄生虫,占 33.3%(21/63),其次是组织溶解性大肠杆菌,占 17%(11/63),羊角风嗜血杆菌占 14.3%(9/63)。在病毒载量大于 1000cps/ml (p = 0.035)、WHO 4 期 (p = 0.002)、CD4 3 (p = 0.001)和光脚行走 (p = 0.001) 的人群中,寄生虫感染率明显较高:结论:在研究地区,艾滋病毒/艾滋病患者的 IP 感染率中等偏高。病毒载量高、世卫组织第 4 阶段、CD4 3 和赤脚对寄生虫比例有很大影响;这给卫生专业人员、卫生规划人员和社区卫生工作者提供了宝贵的启示。因此,要定期对艾滋病毒/艾滋病患者进行病毒载量监测和世卫组织阶段控制评估。为提高艾滋病毒/艾滋病患者的生活质量,定期倡导健康教育、提高认识、常规粪便检查和环境卫生。
{"title":"Magnitude of intestinal parasitic infections and its determinants among HIV/AIDS patients attending at antiretroviral treatment centers in East and West Gojam Zones, Northwest, Ethiopia: institution based cross-sectional study.","authors":"Mengistu Endalamaw, Abel Alemneh, Gashaw Azanaw Amare, Abebe Fenta, Habtamu Belew","doi":"10.1186/s12981-024-00618-3","DOIUrl":"10.1186/s12981-024-00618-3","url":null,"abstract":"<p><strong>Background: </strong>Intestinal parasitic infections (IP) are a major source of morbidity in people living with Human immunodeficiency virus (HIV), particularly in resource-limited settings, mostly as a result of high viral load. Hence, this study aimed to investigate the magnitude of intestinal parasitic infections and its determinants among patients with HIV/AIDS attending public health facilities in East and West Gojam Zones in Ethiopia.</p><p><strong>Methods: </strong>Institution-based cross-sectional study was conducted on 327 people living with HIV visiting public health facilities from December 2022 to May 2023. A simple random sampling technique was used to recruit participants. Face-to-face interviews were used to collect socio-demographics and determinants. The fresh stool was collected from each patient, transported, and tested in accordance with laboratory standard operating procedures of wet mount, formol-ether concentration technique, and modified acid-fast staining. Data were entered and analyzed in the statistical package for Social Science (SPSS) version 20. A 95% CI with p-value < 0.05 was considered statistically significant.</p><p><strong>Results: </strong>The overall prevalence of IP in patients with HIV/AIDS was 19.3% (63/327). Hookworm was the most identified parasite 33.3% (21/63) followed by E.histolytica 17% (11/63) and G.lamblia 14.3% (9/63). Parasitic infections were significantly higher among viral load > 1000cps/ml (p = 0.035), WHO stage 4 (p = 0.002), CD4 < 200 cell/mm<sup>3</sup> (p = 0.001), and bare foot walking (p = 0.001).</p><p><strong>Conclusion: </strong>IP infections are moderately high among patients with HIV/AIDS in the study area. The proportion of parasites was greatly affected by high viral load, WHO stage 4, CD4 < 200 cell/mm<sup>3</sup>, and being barefoot; this gives valuable insight to health professionals, health planners and community health workers. As a result, viral load monitoring, and WHO stage controlling were periodically assessed in patients with HIV/AIDS. Health education, awareness creation, routine stool examination, and environmental hygiene were regularly advocated to increase the life of patients with HIV/AIDS.</p>","PeriodicalId":7503,"journal":{"name":"AIDS Research and Therapy","volume":"21 1","pages":"32"},"PeriodicalIF":2.1,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11097487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140955739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Xpert HIV-1 qual point-of-care testing for HIV early infant diagnosis in Tanzania: experiences and perceptions of health care workers in a 2016 study. 坦桑尼亚用于婴儿艾滋病早期诊断的 Xpert HIV-1 质量护理点检测:2016 年一项研究中医护人员的经验和看法。
IF 2.1 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2024-05-16 DOI: 10.1186/s12981-024-00619-2
Siriel Boniface, Anange Lwilla, Hellen Mahiga, Doreen Pamba, Otto Geisenberger, John France, Rebecca Mokeha, Lilian Njovu, Abisai Kisinda, Nyanda Elias Ntinginya, Michael Hoelscher, Arne Kroidl, Issa Sabi

Background: HIV early infant diagnosis (HEID) at the centralized laboratory faces many challenges that impact the cascade of timely HEID. Point of Care (PoC) HEID has shown to reduce test turnaround times, allow for task shifting and has the potential to reduce infant mortality. We aimed at assessing the feasibility of nurse based PoC-HEID in five facilities of Mbeya region.

Methods: We analysed data from healthcare workers at five obstetric health facilities that participated in the BABY study which enrolled mothers living with HIV and their HIV exposed infants who were followed up until 6 weeks post-delivery. Nurses and laboratory personnel were trained and performed HEID procedures using the Xpert HIV-1 Qual PoC systems. Involved personnel were interviewed on feasibility, knowledge and competency of procedures and overall impression of the use of HIV-1 Qual PoC system in clinical settings.

Results: A total of 28 health care workers (HCWs) who participated in the study between 2014 and 2016 were interviewed, 23 being nurses, 1 clinical officer, 1 lab scientist and 3 lab technicians The median age was 39.5 years. Majority of the nurses (22/24) and all lab staff were confident using Gene Xpert PoC test after being trained. None of them rated Gene Xpert handling as too complicated despite minor challenges. Five HCWs (5/24) reported power cut as the most often occurring problem. As an overall impression, all interviewees agreed on PoC HEID to be used in clinical settings however, about half of them (11/24) indicated that the PoC-HEID procedures add a burden onto their routine workload.

Conclusion: Overall, health care workers in our study demonstrated very good perceptions and experiences of using PoC HEID. Efforts should be invested on quality training, targeted task distribution at the clinics, continual supportive supervision and power back up mechanisms to make the wide-scale adoption of nurse based PoC HEID testing a possibility.

背景:集中实验室的婴儿艾滋病早期诊断(HEID)工作面临着许多挑战,这些挑战影响了婴儿艾滋病早期诊断的及时性。实践证明,护理点(PoC)婴儿艾滋病早期诊断(HEID)可缩短检测周转时间,实现任务转移,并有可能降低婴儿死亡率。我们的目的是评估在姆贝亚地区的五家医疗机构开展以护士为基础的 PoC-HEID 的可行性:我们分析了参与 BABY 研究的五家产科医疗机构的医护人员提供的数据,该研究招募了感染 HIV 的母亲及其感染 HIV 的婴儿,并对其进行随访至分娩后 6 周。护士和实验室人员接受了培训,并使用 Xpert HIV-1 Qual PoC 系统执行了 HEID 程序。对相关人员进行了访谈,内容涉及程序的可行性、知识和能力,以及在临床环境中使用 HIV-1 Qual PoC 系统的总体印象:共有 28 名医护人员(HCWs)在 2014 年至 2016 年间参与了该研究,其中 23 人为护士,1 人为临床官员,1 人为实验室科学家,3 人为实验室技术人员。大多数护士(22/24)和所有实验室工作人员在接受培训后都有信心使用基因 Xpert PoC 检测。尽管存在一些小问题,但没有人认为基因 Xpert 的操作过于复杂。五名医护人员(5/24)报告说,断电是最经常出现的问题。总体印象是,所有受访者都同意在临床环境中使用PoC-HEID,但约有一半受访者(11/24)表示,PoC-HEID程序给他们的日常工作量增加了负担:总体而言,在我们的研究中,医护人员对使用 PoC HEID 有非常好的认识和经验。应努力开展高质量的培训、在诊所进行有针对性的任务分配、持续的支持性监督和后备电源机制,以便能够广泛采用基于护士的 PoC HEID 检测。
{"title":"Xpert HIV-1 qual point-of-care testing for HIV early infant diagnosis in Tanzania: experiences and perceptions of health care workers in a 2016 study.","authors":"Siriel Boniface, Anange Lwilla, Hellen Mahiga, Doreen Pamba, Otto Geisenberger, John France, Rebecca Mokeha, Lilian Njovu, Abisai Kisinda, Nyanda Elias Ntinginya, Michael Hoelscher, Arne Kroidl, Issa Sabi","doi":"10.1186/s12981-024-00619-2","DOIUrl":"10.1186/s12981-024-00619-2","url":null,"abstract":"<p><strong>Background: </strong>HIV early infant diagnosis (HEID) at the centralized laboratory faces many challenges that impact the cascade of timely HEID. Point of Care (PoC) HEID has shown to reduce test turnaround times, allow for task shifting and has the potential to reduce infant mortality. We aimed at assessing the feasibility of nurse based PoC-HEID in five facilities of Mbeya region.</p><p><strong>Methods: </strong>We analysed data from healthcare workers at five obstetric health facilities that participated in the BABY study which enrolled mothers living with HIV and their HIV exposed infants who were followed up until 6 weeks post-delivery. Nurses and laboratory personnel were trained and performed HEID procedures using the Xpert HIV-1 Qual PoC systems. Involved personnel were interviewed on feasibility, knowledge and competency of procedures and overall impression of the use of HIV-1 Qual PoC system in clinical settings.</p><p><strong>Results: </strong>A total of 28 health care workers (HCWs) who participated in the study between 2014 and 2016 were interviewed, 23 being nurses, 1 clinical officer, 1 lab scientist and 3 lab technicians The median age was 39.5 years. Majority of the nurses (22/24) and all lab staff were confident using Gene Xpert PoC test after being trained. None of them rated Gene Xpert handling as too complicated despite minor challenges. Five HCWs (5/24) reported power cut as the most often occurring problem. As an overall impression, all interviewees agreed on PoC HEID to be used in clinical settings however, about half of them (11/24) indicated that the PoC-HEID procedures add a burden onto their routine workload.</p><p><strong>Conclusion: </strong>Overall, health care workers in our study demonstrated very good perceptions and experiences of using PoC HEID. Efforts should be invested on quality training, targeted task distribution at the clinics, continual supportive supervision and power back up mechanisms to make the wide-scale adoption of nurse based PoC HEID testing a possibility.</p>","PeriodicalId":7503,"journal":{"name":"AIDS Research and Therapy","volume":"21 1","pages":"33"},"PeriodicalIF":2.1,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11097447/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140955740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rapid antiretroviral therapy initiation following rollout of point-of-care early infant diagnosis testing, Uganda, 2018-2021. 2018-2021 年乌干达推广护理点婴儿早期诊断检测后快速启动抗逆转录病毒疗法。
IF 2.1 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2024-05-15 DOI: 10.1186/s12981-024-00613-8
Stella M Migamba, Tamara Nsubuga Nyombi, Edirisa Juniour Nsubuga, Andrew Kwiringira, Augustina Delaney, Steven Ndugwa Kabwama, Mary Nakafeero, Benon Kwesiga, Daniel Kadobera, Phoebe Monalisa-Mayambala, Lilian Bulage, Alex Riolexus Ario, Julie R Harris

Background: Uganda Ministry of Health (MOH) recommends a first HIV DNA-PCR test at 4-6 weeks for early infant diagnosis (EID) of HIV-exposed infants (HEI) and immediate return of results. WHO recommends initiating antiretroviral therapy (ART) ≤ 7 days from HIV diagnosis. In 2019, MOH introduced point-of-care (POC) whole-blood EID testing in 33 health facilities and scaled up to 130 facilities in 2020. We assessed results turnaround time and ART linkage pre-POC and during POC testing.

Methods: We evaluated EID register data for HEI at 10 health facilities with POC and EID testing volume of ≥ 12 infants/month from 2018 to 2021. We abstracted data for 12 months before and after POC testing rollout and compared time to sample collection, results receipt, and ART initiation between periods using medians, Wilcoxon, and log-rank tests.

Results: Data for 4.004 HEI were abstracted, of which 1.685 (42%) were from the pre-POC period and 2.319 (58%) were from the period during POC; 3.773 (94%) had a first EID test (pre-POC: 1.649 [44%]; during POC: 2.124 [56%]). Median age at sample collection was 44 (IQR 38-51) days pre-POC and 42 (IQR 33-50) days during POC (p < 0.001). Among 3.773 HEI tested, 3.678 (97%) had test results. HIV-positive infants' (n = 69) median age at sample collection was 94 (IQR 43-124) days pre-POC and 125 (IQR 74-206) days during POC (p = 0.04). HIV positivity rate was 1.6% (27/1.617) pre-POC and 2.0% (42/2.061) during POC (p = 0.43). For all infants, median days from sample collection to results receipt by infants' caregivers was 28 (IQR 14-52) pre-POC and 1 (IQR 0-25) during POC (p < 0.001); among HIV-positive infants, median days were 23 (IQR 7-30) pre-POC and 0 (0-3) during POC (p < 0.001). Pre-POC, 4% (1/23) HIV-positive infants started ART on the sample collection day compared to 33% (12/37) during POC (p < 0.001); ART linkage ≤ 7 days from HIV diagnosis was 74% (17/23) pre-POC and 95% (35/37) during POC (p < 0.001).

Conclusion: POC testing improved EID results turnaround time and ART initiation for HIV-positive infants. While POC testing expansion could further improve ART linkage and loss to follow-up, there is need to explore barriers around same-day ART initiation for infants receiving POC testing.

背景:乌干达卫生部(MOH)建议在 4-6 周时进行首次 HIV DNA-PCR 检测,以便对暴露于 HIV 的婴儿(HEI)进行早期婴儿诊断(EID),并立即返回检测结果。世卫组织建议在艾滋病毒确诊后 7 天内开始抗逆转录病毒疗法(ART)。2019 年,卫生部在 33 家医疗机构引入了护理点(POC)全血 EID 检测,并在 2020 年扩大到 130 家医疗机构。我们评估了 POC 检测前和 POC 检测期间的结果周转时间和 ART 连接情况:我们评估了 10 家医疗机构的 HEI EID 登记数据,这些医疗机构在 2018 年至 2021 年期间的 POC 和 EID 检测量≥ 12 名婴儿/月。我们抽取了 POC 检测推出前后 12 个月的数据,并使用中位数、Wilcoxon 和对数秩检验比较了不同时期的样本采集时间、结果接收时间和抗逆转录病毒疗法启动时间:共摘录了 4 004 例 HEI 的数据,其中 1 685 例(42%)来自 POC 推出前,2 319 例(58%)来自 POC 推出期间;3 773 例(94%)进行了首次 EID 检测(POC 推出前:1 649 例 [44%];POC 推出期间:2 124 例 [56%])。样本采集的中位年龄在 POC 前为 44(IQR 38-51)天,在 POC 期间为 42(IQR 33-50)天(P 结论:POC 测试提高了 EID 结果的转化率:POC 检测缩短了 EID 结果的周转时间,并改善了 HIV 阳性婴儿抗逆转录病毒疗法的启动。尽管 POC 检测的扩大可进一步改善抗逆转录病毒疗法的连接和随访损失,但仍有必要探讨接受 POC 检测的婴儿当天开始抗逆转录病毒疗法的障碍。
{"title":"Rapid antiretroviral therapy initiation following rollout of point-of-care early infant diagnosis testing, Uganda, 2018-2021.","authors":"Stella M Migamba, Tamara Nsubuga Nyombi, Edirisa Juniour Nsubuga, Andrew Kwiringira, Augustina Delaney, Steven Ndugwa Kabwama, Mary Nakafeero, Benon Kwesiga, Daniel Kadobera, Phoebe Monalisa-Mayambala, Lilian Bulage, Alex Riolexus Ario, Julie R Harris","doi":"10.1186/s12981-024-00613-8","DOIUrl":"10.1186/s12981-024-00613-8","url":null,"abstract":"<p><strong>Background: </strong>Uganda Ministry of Health (MOH) recommends a first HIV DNA-PCR test at 4-6 weeks for early infant diagnosis (EID) of HIV-exposed infants (HEI) and immediate return of results. WHO recommends initiating antiretroviral therapy (ART) ≤ 7 days from HIV diagnosis. In 2019, MOH introduced point-of-care (POC) whole-blood EID testing in 33 health facilities and scaled up to 130 facilities in 2020. We assessed results turnaround time and ART linkage pre-POC and during POC testing.</p><p><strong>Methods: </strong>We evaluated EID register data for HEI at 10 health facilities with POC and EID testing volume of ≥ 12 infants/month from 2018 to 2021. We abstracted data for 12 months before and after POC testing rollout and compared time to sample collection, results receipt, and ART initiation between periods using medians, Wilcoxon, and log-rank tests.</p><p><strong>Results: </strong>Data for 4.004 HEI were abstracted, of which 1.685 (42%) were from the pre-POC period and 2.319 (58%) were from the period during POC; 3.773 (94%) had a first EID test (pre-POC: 1.649 [44%]; during POC: 2.124 [56%]). Median age at sample collection was 44 (IQR 38-51) days pre-POC and 42 (IQR 33-50) days during POC (p < 0.001). Among 3.773 HEI tested, 3.678 (97%) had test results. HIV-positive infants' (n = 69) median age at sample collection was 94 (IQR 43-124) days pre-POC and 125 (IQR 74-206) days during POC (p = 0.04). HIV positivity rate was 1.6% (27/1.617) pre-POC and 2.0% (42/2.061) during POC (p = 0.43). For all infants, median days from sample collection to results receipt by infants' caregivers was 28 (IQR 14-52) pre-POC and 1 (IQR 0-25) during POC (p < 0.001); among HIV-positive infants, median days were 23 (IQR 7-30) pre-POC and 0 (0-3) during POC (p < 0.001). Pre-POC, 4% (1/23) HIV-positive infants started ART on the sample collection day compared to 33% (12/37) during POC (p < 0.001); ART linkage ≤ 7 days from HIV diagnosis was 74% (17/23) pre-POC and 95% (35/37) during POC (p < 0.001).</p><p><strong>Conclusion: </strong>POC testing improved EID results turnaround time and ART initiation for HIV-positive infants. While POC testing expansion could further improve ART linkage and loss to follow-up, there is need to explore barriers around same-day ART initiation for infants receiving POC testing.</p>","PeriodicalId":7503,"journal":{"name":"AIDS Research and Therapy","volume":"21 1","pages":"31"},"PeriodicalIF":2.1,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11094911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140943801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Angiolipoma associated with antiretroviral switch therapy: a case report. 与抗逆转录病毒转换疗法相关的血管脂肪瘤:病例报告。
IF 2.1 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2024-05-11 DOI: 10.1186/s12981-024-00620-9
Gregory H Taylor, Neha Sheth Pandit

Background: Angiolipomas have been well described in patients with HIV exposed to protease inhibitors with possible resolution after switching to non-nucleoside reverse transcriptase inhibitor-based regimens. Resolution of symptoms have occurred with switches to non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens; however, little is known regarding the development of angiolipomas when switching from NNRTI- to modern, integrase strand transfer inhibitor-based regimens. We describe a patient who underwent switch therapy from tenofovir disoproxil fumarate/emtricitabine/efavirenz (TDF/FTC/EFV) to tenofovir alafenamide/FTC/bictegravir (TAF/FTC/BIC) who later developed angiolipomas.

Case presentation: A 55-year-old male had been on TDF/FTC/EFV for 8 years before switching to TAF/FTC/BIC. Nineteen months after antiretroviral switch, the patient presented with multiple lesions in the upper extremities and abdomen. Diagnostic biopsies revealed non-encapsulated angiolipomas and HHV-8 and non-alcoholic fatty liver disease was ruled out. New lesions continued to appear 29 months after ART switch, after which now lesions appeared and prior lesions remained stable with no increase in size noted. No surgical intervention or change in antiretroviral therapy was needed.

Conclusions: Angiogenesis may have been suppressed with TDF/FTC/EFV treatment, however when switched to TAF/FTC/BIC, promoted the growth of angiolipomas. Clinicians should be aware of the impact of switching to modern ART therapies resulting in possible adipogenesis.

背景:在接受蛋白酶抑制剂治疗的艾滋病患者中,血管脂肪瘤已被广泛描述,在改用非核苷类逆转录酶抑制剂治疗后,血管脂肪瘤的症状可能会得到缓解。改用非核苷类逆转录酶抑制剂(NNRTI)为基础的治疗方案后,症状有所缓解;然而,从 NNRTI 转为现代整合酶链转移抑制剂为基础的治疗方案后,血管脂肪瘤的发展情况却鲜为人知。我们描述了一名从替诺福韦二吡呋酯/恩曲他滨/依非韦伦(TDF/FTC/EFV)转为替诺福韦阿拉非酰胺/FTC/比特格韦(TAF/FTC/BIC)治疗的患者,他后来出现了血管脂肪瘤:病例简介:一名 55 岁的男性在转用 TAF/FTC/BIC 前已服用 TDF/FTC/EFV 长达 8 年。转用抗逆转录病毒疗法 19 个月后,患者出现上肢和腹部多处病变。诊断性活检发现了非包囊性血管脂肪瘤和 HHV-8,排除了非酒精性脂肪肝。转用抗逆转录病毒疗法 29 个月后,新的病灶继续出现,之后又出现了新的病灶,而之前的病灶保持稳定,没有发现增大。无需进行手术治疗或改变抗逆转录病毒疗法:结论:TDF/FTC/EFV疗法可能抑制了血管生成,但在改用TAF/FTC/BIC疗法后,又促进了血管脂肪瘤的生长。临床医生应意识到改用现代抗逆转录病毒疗法可能导致脂肪生成的影响。
{"title":"Angiolipoma associated with antiretroviral switch therapy: a case report.","authors":"Gregory H Taylor, Neha Sheth Pandit","doi":"10.1186/s12981-024-00620-9","DOIUrl":"10.1186/s12981-024-00620-9","url":null,"abstract":"<p><strong>Background: </strong>Angiolipomas have been well described in patients with HIV exposed to protease inhibitors with possible resolution after switching to non-nucleoside reverse transcriptase inhibitor-based regimens. Resolution of symptoms have occurred with switches to non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens; however, little is known regarding the development of angiolipomas when switching from NNRTI- to modern, integrase strand transfer inhibitor-based regimens. We describe a patient who underwent switch therapy from tenofovir disoproxil fumarate/emtricitabine/efavirenz (TDF/FTC/EFV) to tenofovir alafenamide/FTC/bictegravir (TAF/FTC/BIC) who later developed angiolipomas.</p><p><strong>Case presentation: </strong>A 55-year-old male had been on TDF/FTC/EFV for 8 years before switching to TAF/FTC/BIC. Nineteen months after antiretroviral switch, the patient presented with multiple lesions in the upper extremities and abdomen. Diagnostic biopsies revealed non-encapsulated angiolipomas and HHV-8 and non-alcoholic fatty liver disease was ruled out. New lesions continued to appear 29 months after ART switch, after which now lesions appeared and prior lesions remained stable with no increase in size noted. No surgical intervention or change in antiretroviral therapy was needed.</p><p><strong>Conclusions: </strong>Angiogenesis may have been suppressed with TDF/FTC/EFV treatment, however when switched to TAF/FTC/BIC, promoted the growth of angiolipomas. Clinicians should be aware of the impact of switching to modern ART therapies resulting in possible adipogenesis.</p>","PeriodicalId":7503,"journal":{"name":"AIDS Research and Therapy","volume":"21 1","pages":"30"},"PeriodicalIF":2.1,"publicationDate":"2024-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11088114/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140908195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing the resilience of HIV healthcare services provided to adolescents and young adults after the COVID-19 pandemic in the city of Beira (Mozambique): an interrupted time series analysis. 评估莫桑比克贝拉市在 COVID-19 大流行后为青少年和年轻成人提供的艾滋病毒医疗保健服务的复原力:间断时间序列分析。
IF 2.1 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2024-05-09 DOI: 10.1186/s12981-024-00621-8
Roberto Benoni, Francesco Cavallin, Virginia Casigliani, Annachiara Zin, Dara Giannini, Izilda Chaguruca, Vasco Cinturao, Fernando Chinene, Giulia Brigadoi, Daniele Donà, Giovanni Putoto, Carlo Giaquinto

Background: The COVID-19 pandemic has put the provision of health services globally at risk. In Sub-Saharan Africa, it had a major impact on HIV services. However, there is a lack of data on the post-pandemic period. This study aims to evaluate the resumption of HIV services and retention in care for adolescents and young people in the period following the COVID-19 pandemic.

Methods: A retrospective cohort study was conducted using interrupted time series analysis. Three periods were considered: pre-pandemic (form June 2019 to March 2020), pandemic (form April 2020 to March 2022) post-pandemic (from April 2022 to March 2023). Six outcome measures were considered: number of outpatient visits, HIV tests, HIV positivity ratio, the antiretroviral treatment (ART) non-adherence ratio, recall ratio, and the return ratio for adolescent and young adults on ART.

Results: During the study period, 447,515 outpatient visits and 126,096 HIV tests were recorded. After a reduction at the beginning of the pandemic period, both visits and tests increased during the pandemic (p < 0.05) and decreased in the post-pandemic (p < 0.05), recovering the pre-pandemic trends. The HIV positivity ratio slightly decreased from 3.3% to 1.7% during the study period (p < 0.05). The ART non-adherence ratio decreased from 23.4% to 2.4% throughout the study period (p < 0.05), with a drop at the beginning of the post-pandemic period (p < 0.05). The recall ratio increased during the study period (p < 0.05) with a drop at the beginning of the pandemic and post-pandemic periods (p < 0.05). The return ratio decreased at the beginning of the pandemic (p < 0.05) but returned to the pre-pandemic ratio in the post-pandemic period.

Conclusions: The post-pandemic values of the investigated outcomes were comparable to pre-pandemic period, or even improved. Differently from other services, such as the community activities, that have been severely affected by COVID-19 pandemic, the HIV service system has shown resilience following emergency situation.

背景:COVID-19 大流行使全球的医疗服务面临风险。在撒哈拉以南非洲,它对艾滋病服务产生了重大影响。然而,目前还缺乏大流行后的数据。本研究旨在评估 COVID-19 大流行后青少年艾滋病服务的恢复情况和继续接受治疗的情况:方法:采用间断时间序列分析法进行了一项回顾性队列研究。研究考虑了三个时期:大流行前(2019 年 6 月至 2020 年 3 月)、大流行(2020 年 4 月至 2022 年 3 月)和大流行后(2022 年 4 月至 2023 年 3 月)。研究考虑了六项结果指标:门诊次数、HIV 检测、HIV 阳性率、抗逆转录病毒疗法(ART)不依从率、召回率以及青少年和年轻成年人接受抗逆转录病毒疗法的回访率:在研究期间,共记录了 447 515 次门诊就诊和 126 096 次 HIV 检测。在大流行初期,门诊量和检测量都有所下降,但在大流行期间,门诊量和检测量都有所上升(p 结论):大流行后的调查结果与大流行前相当,甚至有所改善。与受到 COVID-19 大流行严重影响的其他服务(如社区活动)不同,艾滋病服务系统在紧急情况下表现出了顽强的生命力。
{"title":"Assessing the resilience of HIV healthcare services provided to adolescents and young adults after the COVID-19 pandemic in the city of Beira (Mozambique): an interrupted time series analysis.","authors":"Roberto Benoni, Francesco Cavallin, Virginia Casigliani, Annachiara Zin, Dara Giannini, Izilda Chaguruca, Vasco Cinturao, Fernando Chinene, Giulia Brigadoi, Daniele Donà, Giovanni Putoto, Carlo Giaquinto","doi":"10.1186/s12981-024-00621-8","DOIUrl":"10.1186/s12981-024-00621-8","url":null,"abstract":"<p><strong>Background: </strong>The COVID-19 pandemic has put the provision of health services globally at risk. In Sub-Saharan Africa, it had a major impact on HIV services. However, there is a lack of data on the post-pandemic period. This study aims to evaluate the resumption of HIV services and retention in care for adolescents and young people in the period following the COVID-19 pandemic.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted using interrupted time series analysis. Three periods were considered: pre-pandemic (form June 2019 to March 2020), pandemic (form April 2020 to March 2022) post-pandemic (from April 2022 to March 2023). Six outcome measures were considered: number of outpatient visits, HIV tests, HIV positivity ratio, the antiretroviral treatment (ART) non-adherence ratio, recall ratio, and the return ratio for adolescent and young adults on ART.</p><p><strong>Results: </strong>During the study period, 447,515 outpatient visits and 126,096 HIV tests were recorded. After a reduction at the beginning of the pandemic period, both visits and tests increased during the pandemic (p < 0.05) and decreased in the post-pandemic (p < 0.05), recovering the pre-pandemic trends. The HIV positivity ratio slightly decreased from 3.3% to 1.7% during the study period (p < 0.05). The ART non-adherence ratio decreased from 23.4% to 2.4% throughout the study period (p < 0.05), with a drop at the beginning of the post-pandemic period (p < 0.05). The recall ratio increased during the study period (p < 0.05) with a drop at the beginning of the pandemic and post-pandemic periods (p < 0.05). The return ratio decreased at the beginning of the pandemic (p < 0.05) but returned to the pre-pandemic ratio in the post-pandemic period.</p><p><strong>Conclusions: </strong>The post-pandemic values of the investigated outcomes were comparable to pre-pandemic period, or even improved. Differently from other services, such as the community activities, that have been severely affected by COVID-19 pandemic, the HIV service system has shown resilience following emergency situation.</p>","PeriodicalId":7503,"journal":{"name":"AIDS Research and Therapy","volume":"21 1","pages":"29"},"PeriodicalIF":2.1,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11080168/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140896432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The importance of self-management for better treatment outcomes for HIV patients in a low-income setting: perspectives of HIV experts and service providers 在低收入环境中,自我管理对提高艾滋病患者治疗效果的重要性:艾滋病专家和服务提供者的观点
IF 2.2 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2024-05-04 DOI: 10.1186/s12981-024-00612-9
Tegene Legese Dadi, Yadessa Tegene, Nienke Vollebregt, Girmay Medhin, Mark Spigt
Self-management is the most important strategy to improve quality of life in patients with a chronic disease. Despite the increasing number of people living with HIV (PLWH) in low-income countries, very little research on self-management is conducted in this setting. The aim of this research is to understand the perspectives of service providers and experts on the importance of self-management for PLWH. A systematizing expert interview type of qualitative methodology was used to gain the perspectives of experts and service providers. The study participants had experience in researching, managing, or providing HIV service in east and southern African (ESA) countries. All the interviews were audio recorded, transcribed, and translated to English. The quality of the transcripts was ensured by randomly checking the texts against the audio record. A thematic analysis approach supported by Atlas TI version 9 software. PLWH face a variety of multi-dimensional problems thematized under contextual and process dimensions. The problems identified under the contextual dimension include disease-specific, facility-related, and social environment-related. Problems with individual origin, such as ignorance, outweighing beliefs over scientific issues, low self-esteem, and a lack of social support, were mostly highlighted under the process dimensions. Those problems have a deleterious impact on self-management, treatment outcomes, and the quality of life of PLWH. Low self-management is also a result of professional-centered service delivery in healthcare facilities and health service providers’ incapacity to comprehend a patient’s need beyond the medical concerns. Participants in the study asserted that patients have a significant stake in enhancing treatment results and quality of life through enhancing self-management. HIV patients face multifaceted problems beyond their medical issues. The success of medical treatment for HIV is strongly contingent upon patients’ self-management practices and the supportive roles of their family, society, and health service providers. The development and integration of self-management practices into clinical care will benefit patients, their families, and the health system.
自我管理是提高慢性病患者生活质量的最重要策略。尽管低收入国家的艾滋病病毒感染者(PLWH)人数不断增加,但在这种情况下开展的有关自我管理的研究却少之又少。本研究旨在了解服务提供者和专家对艾滋病毒感染者自我管理重要性的看法。研究采用了系统化的专家访谈定性方法,以了解专家和服务提供者的观点。研究参与者在东部和南部非洲(ESA)国家具有研究、管理或提供艾滋病服务的经验。所有访谈都进行了录音、转录并翻译成英文。通过将文本与录音进行随机核对,确保了记录誊本的质量。采用 Atlas TI 第 9 版软件支持的主题分析方法。PLWH 面临着各种多维度的问题,这些问题被归纳为背景维度和过程维度。在背景维度下确定的问题包括与疾病有关、与设施有关和与社会环境有关的问题。在过程维度下,主要强调的是源于个人的问题,如无知、对科学问题的信念过强、自卑和缺乏社会支持。这些问题对 PLWH 的自我管理、治疗效果和生活质量产生了有害影响。自我管理程度低也是医疗机构以专业为中心提供服务以及医疗服务提供者无法理解患者在医疗问题之外的需求的结果。本研究的参与者认为,通过加强自我管理来提高治疗效果和生活质量与患者息息相关。艾滋病患者面临着医疗问题之外的多方面问题。艾滋病毒医疗的成功与否,在很大程度上取决于患者的自我管理实践以及家庭、社会和医疗服务提供者的支持作用。发展自我管理实践并将其纳入临床护理将使患者、其家庭和医疗系统受益。
{"title":"The importance of self-management for better treatment outcomes for HIV patients in a low-income setting: perspectives of HIV experts and service providers","authors":"Tegene Legese Dadi, Yadessa Tegene, Nienke Vollebregt, Girmay Medhin, Mark Spigt","doi":"10.1186/s12981-024-00612-9","DOIUrl":"https://doi.org/10.1186/s12981-024-00612-9","url":null,"abstract":"Self-management is the most important strategy to improve quality of life in patients with a chronic disease. Despite the increasing number of people living with HIV (PLWH) in low-income countries, very little research on self-management is conducted in this setting. The aim of this research is to understand the perspectives of service providers and experts on the importance of self-management for PLWH. A systematizing expert interview type of qualitative methodology was used to gain the perspectives of experts and service providers. The study participants had experience in researching, managing, or providing HIV service in east and southern African (ESA) countries. All the interviews were audio recorded, transcribed, and translated to English. The quality of the transcripts was ensured by randomly checking the texts against the audio record. A thematic analysis approach supported by Atlas TI version 9 software. PLWH face a variety of multi-dimensional problems thematized under contextual and process dimensions. The problems identified under the contextual dimension include disease-specific, facility-related, and social environment-related. Problems with individual origin, such as ignorance, outweighing beliefs over scientific issues, low self-esteem, and a lack of social support, were mostly highlighted under the process dimensions. Those problems have a deleterious impact on self-management, treatment outcomes, and the quality of life of PLWH. Low self-management is also a result of professional-centered service delivery in healthcare facilities and health service providers’ incapacity to comprehend a patient’s need beyond the medical concerns. Participants in the study asserted that patients have a significant stake in enhancing treatment results and quality of life through enhancing self-management. HIV patients face multifaceted problems beyond their medical issues. The success of medical treatment for HIV is strongly contingent upon patients’ self-management practices and the supportive roles of their family, society, and health service providers. The development and integration of self-management practices into clinical care will benefit patients, their families, and the health system.","PeriodicalId":7503,"journal":{"name":"AIDS Research and Therapy","volume":"11 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140838778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The association between single-nucleotide polymorphisms within type 1 interferon pathway genes and human immunodeficiency virus type 1 viral load in antiretroviral-naïve participants 抗逆转录病毒药物无效者体内 1 型干扰素通路基因的单核苷酸多态性与 1 型人类免疫缺陷病毒病毒载量之间的关系
IF 2.2 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2024-05-03 DOI: 10.1186/s12981-024-00610-x
Sara Bohnstedt Mørup, Preston Leung, Cavan Reilly, Brad T. Sherman, Weizhong Chang, Maja Milojevic, Ana Milinkovic, Angelike Liappis, Line Borgwardt, Kathy Petoumenos, Roger Paredes, Shweta S. Mistry, Cameron R. MacPherson, Jens Lundgren, Marie Helleberg, Joanne Reekie, Daniel D. Murray
Human genetic contribution to HIV progression remains inadequately explained. The type 1 interferon (IFN) pathway is important for host control of HIV and variation in type 1 IFN genes may contribute to disease progression. This study assessed the impact of variations at the gene and pathway level of type 1 IFN on HIV-1 viral load (VL). Two cohorts of antiretroviral (ART) naïve participants living with HIV (PLWH) with either early (START) or advanced infection (FIRST) were analysed separately. Type 1 IFN genes (n = 17) and receptor subunits (IFNAR1, IFNAR2) were examined for both cumulated type 1 IFN pathway analysis and individual gene analysis. SKAT-O was applied to detect associations between the genotype and HIV-1 study entry viral load (log10 transformed) as a proxy for set point VL; P-values were corrected using Bonferroni (P < 0.0025). The analyses among those with early infection included 2429 individuals from five continents. The median study entry HIV VL was 14,623 (IQR 3460–45100) copies/mL. Across 673 SNPs within 19 type 1 IFN genes, no significant association with study entry VL was detected. Conversely, examining individual genes in START showed a borderline significant association between IFNW1, and study entry VL (P = 0.0025). This significance remained after separate adjustments for age, CD4+ T-cell count, CD4+/CD8+ T-cell ratio and recent infection. When controlling for population structure using linear mixed effects models (LME), in addition to principal components used in the main model, this was no longer significant (p = 0.0244). In subgroup analyses stratified by geographical region, the association between IFNW1 and study entry VL was only observed among African participants, although, the association was not significant when controlling for population structure using LME. Of the 17 SNPs within the IFNW1 region, only rs79876898 (A > G) was associated with study entry VL (p = 0.0020, beta = 0.32; G associated with higher study entry VL than A) in single SNP association analyses. The findings were not reproduced in FIRST participants. Across 19 type 1 IFN genes, only IFNW1 was associated with HIV-1 study entry VL in a cohort of ART-naïve individuals in early stages of their infection, however, this was no longer significant in sensitivity analyses that controlled for population structures using LME.
人类基因对艾滋病进展的影响仍未得到充分解释。1 型干扰素(IFN)通路对宿主控制 HIV 很重要,而 1 型 IFN 基因的变异可能会导致疾病进展。本研究评估了 1 型 IFN 基因和途径水平的变异对 HIV-1 病毒载量(VL)的影响。研究分别分析了两个队列的抗逆转录病毒疗法(ART)新感染者(PLWH),他们要么是早期感染者(START),要么是晚期感染者(FIRST)。对 1 型 IFN 基因(n = 17)和受体亚基(IFNAR1、IFNAR2)进行了累积 1 型 IFN 通路分析和单个基因分析。在单个 SNP 关联分析中,应用 SKAT-O 检测基因型与作为设定点 VL 代表的 HIV-1 研究初始病毒载量(对数 10 转换)之间的关联;使用 Bonferroni 校正 P 值(P G)与研究初始 VL 相关(P = 0.0020,β = 0.32;G 与研究初始 VL 高于 A 相关)。这些发现在 FIRST 参与者中没有再现。在 19 个 1 型 IFN 基因中,只有 IFNW1 与感染早期抗逆转录病毒疗法(ART)无效者队列中的 HIV-1 入组 VL 相关,但在使用 LME 控制人群结构的敏感性分析中,这一结果不再显著。
{"title":"The association between single-nucleotide polymorphisms within type 1 interferon pathway genes and human immunodeficiency virus type 1 viral load in antiretroviral-naïve participants","authors":"Sara Bohnstedt Mørup, Preston Leung, Cavan Reilly, Brad T. Sherman, Weizhong Chang, Maja Milojevic, Ana Milinkovic, Angelike Liappis, Line Borgwardt, Kathy Petoumenos, Roger Paredes, Shweta S. Mistry, Cameron R. MacPherson, Jens Lundgren, Marie Helleberg, Joanne Reekie, Daniel D. Murray","doi":"10.1186/s12981-024-00610-x","DOIUrl":"https://doi.org/10.1186/s12981-024-00610-x","url":null,"abstract":"Human genetic contribution to HIV progression remains inadequately explained. The type 1 interferon (IFN) pathway is important for host control of HIV and variation in type 1 IFN genes may contribute to disease progression. This study assessed the impact of variations at the gene and pathway level of type 1 IFN on HIV-1 viral load (VL). Two cohorts of antiretroviral (ART) naïve participants living with HIV (PLWH) with either early (START) or advanced infection (FIRST) were analysed separately. Type 1 IFN genes (n = 17) and receptor subunits (IFNAR1, IFNAR2) were examined for both cumulated type 1 IFN pathway analysis and individual gene analysis. SKAT-O was applied to detect associations between the genotype and HIV-1 study entry viral load (log10 transformed) as a proxy for set point VL; P-values were corrected using Bonferroni (P < 0.0025). The analyses among those with early infection included 2429 individuals from five continents. The median study entry HIV VL was 14,623 (IQR 3460–45100) copies/mL. Across 673 SNPs within 19 type 1 IFN genes, no significant association with study entry VL was detected. Conversely, examining individual genes in START showed a borderline significant association between IFNW1, and study entry VL (P = 0.0025). This significance remained after separate adjustments for age, CD4+ T-cell count, CD4+/CD8+ T-cell ratio and recent infection. When controlling for population structure using linear mixed effects models (LME), in addition to principal components used in the main model, this was no longer significant (p = 0.0244). In subgroup analyses stratified by geographical region, the association between IFNW1 and study entry VL was only observed among African participants, although, the association was not significant when controlling for population structure using LME. Of the 17 SNPs within the IFNW1 region, only rs79876898 (A > G) was associated with study entry VL (p = 0.0020, beta = 0.32; G associated with higher study entry VL than A) in single SNP association analyses. The findings were not reproduced in FIRST participants. Across 19 type 1 IFN genes, only IFNW1 was associated with HIV-1 study entry VL in a cohort of ART-naïve individuals in early stages of their infection, however, this was no longer significant in sensitivity analyses that controlled for population structures using LME.","PeriodicalId":7503,"journal":{"name":"AIDS Research and Therapy","volume":"22 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140838781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Presence of tuberculosis symptoms among HIV-positive men who have sex with men (MSM) in Zimbabwe 更正:津巴布韦艾滋病毒呈阳性的男男性行为者(MSM)中出现结核病症状的情况
IF 2.2 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2024-04-29 DOI: 10.1186/s12981-024-00617-4
Munyaradzi Mapingure, Innocent Chingombe, Tafadzwa Dzinamarira, Brian Moyo, Chesterfield Samba, Delight Murigo, Owen Mugurungi, Elliot Mbunge, Rutendo Birri Makota, Grant Murewanhema, Godfrey Musuka
<p><b>Correction to: AIDS Research and Therapy (2024) 21:18</b></p><p><b>https://doi.org/10.1186/s12981-024-00605-8</b>.</p><p>In this article [1], the statement in the Funding information section was incorrectly given as ‘The study was not funded’ and should have read ’ The secondary data analysis was not funded’.</p><ol data-track-component="outbound reference"><li data-counter="1."><p>Mapingure M, Chingombe I, Dzinamarira T, Moyo B, Samba C, Murigo D, Mugurungi O, Mbunge E, Makota RB, Murewanhema G, Musuka G. Presence of tuberculosis symptoms among HIV-positive men who have sex with men (MSM) in Zimbabwe. AIDS Res Ther. 2024;21(1):18.</p></li></ol><p>Download references<svg aria-hidden="true" focusable="false" height="16" role="img" width="16"><use xlink:href="#icon-eds-i-download-medium" xmlns:xlink="http://www.w3.org/1999/xlink"></use></svg></p><h3>Authors and Affiliations</h3><ol><li><p>ICAP in Zimbabwe, Harare, Zimbabwe</p><p>Munyaradzi Mapingure, Innocent Chingombe & Tafadzwa Dzinamarira</p></li><li><p>AIDS and TB Programmes, Ministry of Health and Child Care, Harare, Zimbabwe</p><p>Brian Moyo & Owen Mugurungi</p></li><li><p>GALZ, Harare, Zimbabwe</p><p>Chesterfield Samba & Delight Murigo</p></li><li><p>Department of Computer Science, Faculty of Science and Engineering, University of Eswatini, Kwaluseni, Eswatini</p><p>Elliot Mbunge</p></li><li><p>Department of Biological Sciences and Ecology, University of Zimbabwe, Harare, Zimbabwe</p><p>Rutendo Birri Makota</p></li><li><p>Unit of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe</p><p>Grant Murewanhema</p></li><li><p>International Initiative for Impact Evaluation, Harare, Zimbabwe</p><p>Godfrey Musuka</p></li></ol><span>Authors</span><ol><li><span>Munyaradzi Mapingure</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Innocent Chingombe</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Tafadzwa Dzinamarira</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Brian Moyo</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Chesterfield Samba</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Delight Murigo</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Owen Mugurungi</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Elliot Mbunge</span>View author publications<p>You can also search for this author in <span>PubMed<span
更正:AIDS Research and Therapy (2024) 21:18https://doi.org/10.1186/s12981-024-00605-8.In 这篇文章[1]中,资助信息部分的声明错误地表述为 "该研究未获得资助",应为 "二次数据分析未获得资助"。Mapingure M, Chingombe I, Dzinamarira T, Moyo B, Samba C, Murigo D, Mugurungi O, Mbunge E, Makota RB, Murewanhema G, Musuka G. 津巴布韦 HIV 阳性男男性行为者 (MSM) 中结核病症状的存在。AIDS Res Ther.2024;21(1):18.下载参考文献作者和单位津巴布韦国际艾滋病规划署,哈拉雷,津巴布韦Munyaradzi Mapingure, Innocent Chingombe & Tafadzwa Dzinamarira艾滋病和结核病计划,卫生和儿童保健部,哈拉雷,津巴布韦Brian Moyo & Owen MugurungiGALZ,哈拉雷,津巴布韦Chesterfield Samba &;Delight MurigoDepartment of Computer Science, Faculty of Science and Engineering, University of Eswatini, Kwaluseni, EswatiniElliot MbungeDepartment of Biological Sciences and Ecology, University of Zimbabwe, Harare, ZimbabweRutendo Birri MakotaUnit of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, ZimbabweGrant MurewanhemaInternational Initiative for Impact Evaluation, Harare、津巴布韦Godfrey Musuka作者Munyaradzi Mapingure查看作者发表的文章您也可以在PubMed谷歌学术中搜索该作者Innocent Chingombe查看作者发表的文章您也可以在PubMed谷歌学术中搜索该作者Tafadzwa Dzinamarira查看作者发表的文章您也可以在PubMed谷歌学术中搜索该作者您也可以在 PubMed Google Scholar中搜索这位作者Owen Mugurungi查看作者发表的作品您也可以在 PubMed Google Scholar中搜索这位作者Elliot Mbunge查看作者发表的作品您也可以在 PubMed Google Scholar中搜索这位作者Rutendo Birri Makota查看作者发表的作品您也可以在 PubMed Google Scholar中搜索这位作者您也可以在 PubMed Google Scholar 中搜索该作者Grant Murewanhema查看作者发表的作品您也可以在 PubMed Google Scholar 中搜索该作者Godfrey Musuka查看作者发表的作品您也可以在 PubMed Google Scholar 中搜索该作者通信作者:Godfrey Musuka。出版者注Springer Nature对已出版地图中的管辖权主张和机构隶属关系保持中立。原文的在线版本可在以下网址找到:https://doi.org/10.1186/s12981-024-00605-8.Open Access 本文采用知识共享署名 4.0 国际许可协议进行许可,该协议允许以任何媒介或格式使用、共享、改编、分发和复制,只要您适当注明原作者和来源,提供知识共享许可协议的链接,并说明是否进行了修改。本文中的图片或其他第三方材料均包含在文章的知识共享许可协议中,除非在材料的署名栏中另有说明。如果材料未包含在文章的知识共享许可协议中,且您打算使用的材料不符合法律规定或超出许可使用范围,则您需要直接从版权所有者处获得许可。要查看该许可的副本,请访问 http://creativecommons.org/licenses/by/4.0/。除非在数据的信用行中另有说明,否则知识共享公共领域专用免责声明(http://creativecommons.org/publicdomain/zero/1.0/)适用于本文提供的数据。转载与许可引用本文Mapingure, M., Chingombe, I., Dzinamarira, T. et al. Correction:津巴布韦 HIV 阳性男男性行为者(MSM)的结核病症状。AIDS Res Ther 21, 26 (2024). https://doi.org/10.1186/s12981-024-00617-4Download citationAccepted:12 April 2024Published: 29 April 2024DOI: https://doi.org/10.1186/s12981-024-00617-4Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative
{"title":"Correction: Presence of tuberculosis symptoms among HIV-positive men who have sex with men (MSM) in Zimbabwe","authors":"Munyaradzi Mapingure, Innocent Chingombe, Tafadzwa Dzinamarira, Brian Moyo, Chesterfield Samba, Delight Murigo, Owen Mugurungi, Elliot Mbunge, Rutendo Birri Makota, Grant Murewanhema, Godfrey Musuka","doi":"10.1186/s12981-024-00617-4","DOIUrl":"https://doi.org/10.1186/s12981-024-00617-4","url":null,"abstract":"&lt;p&gt;&lt;b&gt;Correction to: AIDS Research and Therapy (2024) 21:18&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;https://doi.org/10.1186/s12981-024-00605-8&lt;/b&gt;.&lt;/p&gt;&lt;p&gt;In this article [1], the statement in the Funding information section was incorrectly given as ‘The study was not funded’ and should have read ’ The secondary data analysis was not funded’.&lt;/p&gt;&lt;ol data-track-component=\"outbound reference\"&gt;&lt;li data-counter=\"1.\"&gt;&lt;p&gt;Mapingure M, Chingombe I, Dzinamarira T, Moyo B, Samba C, Murigo D, Mugurungi O, Mbunge E, Makota RB, Murewanhema G, Musuka G. Presence of tuberculosis symptoms among HIV-positive men who have sex with men (MSM) in Zimbabwe. AIDS Res Ther. 2024;21(1):18.&lt;/p&gt;&lt;/li&gt;&lt;/ol&gt;&lt;p&gt;Download references&lt;svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"&gt;&lt;use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"&gt;&lt;/use&gt;&lt;/svg&gt;&lt;/p&gt;&lt;h3&gt;Authors and Affiliations&lt;/h3&gt;&lt;ol&gt;&lt;li&gt;&lt;p&gt;ICAP in Zimbabwe, Harare, Zimbabwe&lt;/p&gt;&lt;p&gt;Munyaradzi Mapingure, Innocent Chingombe &amp; Tafadzwa Dzinamarira&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;AIDS and TB Programmes, Ministry of Health and Child Care, Harare, Zimbabwe&lt;/p&gt;&lt;p&gt;Brian Moyo &amp; Owen Mugurungi&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;GALZ, Harare, Zimbabwe&lt;/p&gt;&lt;p&gt;Chesterfield Samba &amp; Delight Murigo&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;Department of Computer Science, Faculty of Science and Engineering, University of Eswatini, Kwaluseni, Eswatini&lt;/p&gt;&lt;p&gt;Elliot Mbunge&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;Department of Biological Sciences and Ecology, University of Zimbabwe, Harare, Zimbabwe&lt;/p&gt;&lt;p&gt;Rutendo Birri Makota&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;Unit of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe&lt;/p&gt;&lt;p&gt;Grant Murewanhema&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;International Initiative for Impact Evaluation, Harare, Zimbabwe&lt;/p&gt;&lt;p&gt;Godfrey Musuka&lt;/p&gt;&lt;/li&gt;&lt;/ol&gt;&lt;span&gt;Authors&lt;/span&gt;&lt;ol&gt;&lt;li&gt;&lt;span&gt;Munyaradzi Mapingure&lt;/span&gt;View author publications&lt;p&gt;You can also search for this author in &lt;span&gt;PubMed&lt;span&gt; &lt;/span&gt;Google Scholar&lt;/span&gt;&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;Innocent Chingombe&lt;/span&gt;View author publications&lt;p&gt;You can also search for this author in &lt;span&gt;PubMed&lt;span&gt; &lt;/span&gt;Google Scholar&lt;/span&gt;&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;Tafadzwa Dzinamarira&lt;/span&gt;View author publications&lt;p&gt;You can also search for this author in &lt;span&gt;PubMed&lt;span&gt; &lt;/span&gt;Google Scholar&lt;/span&gt;&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;Brian Moyo&lt;/span&gt;View author publications&lt;p&gt;You can also search for this author in &lt;span&gt;PubMed&lt;span&gt; &lt;/span&gt;Google Scholar&lt;/span&gt;&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;Chesterfield Samba&lt;/span&gt;View author publications&lt;p&gt;You can also search for this author in &lt;span&gt;PubMed&lt;span&gt; &lt;/span&gt;Google Scholar&lt;/span&gt;&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;Delight Murigo&lt;/span&gt;View author publications&lt;p&gt;You can also search for this author in &lt;span&gt;PubMed&lt;span&gt; &lt;/span&gt;Google Scholar&lt;/span&gt;&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;Owen Mugurungi&lt;/span&gt;View author publications&lt;p&gt;You can also search for this author in &lt;span&gt;PubMed&lt;span&gt; &lt;/span&gt;Google Scholar&lt;/span&gt;&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;Elliot Mbunge&lt;/span&gt;View author publications&lt;p&gt;You can also search for this author in &lt;span&gt;PubMed&lt;span","PeriodicalId":7503,"journal":{"name":"AIDS Research and Therapy","volume":"22 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140838715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
AIDS Research and Therapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1